Table 2 Relationship between the expression of PTPRM and clinicopathological parameters of EOC

Age (years)

0.043

 < 50

21

15

71.4

6

28.6

 ≥ 50

36

33

91.7

3

8.3

Clinical stages

0.031

 I + II

32

24

75.0

8

25.0

 III + IV

25

24

96.0

1

4.0

Pathological type

0.339

 Serous carcinoma

32

29

90.6

3

9.4

 Mucinous carcinoma

7

6

85.7

1

14.3

 Clear cell carcinoma

9

6

66.7

3

33.3

 Endometrioid carcinoma

9

7

77.8

2

22.2

Age of menarche (years)

0.227

 < 15

34

27

79.4

7

20.6

 ≥ 15

23

21

91.3

2

8.7

Age of menostasis (years)

0.863

 < 50

17

15

88.2

2

11.8

 ≥ 50

20

18

90.0

2

10.0

Number of pregnancies (times)

0.837

 < 1

3

2

66.7

1

33.3

 ≥ 1

54

46

85.2

8

14.8

Family history of malignant tumors

0.110

 None

46

37

80.4

9

19.6

 Yes

11

11

100.0

0

0

Medical comorbidities

0.802

 None

40

34

85.0

6

15.0

 Yes

17

14

82.4

3

17.6

CA125 (U/ml)

0.587

 < 500

40

33

82.5

7

17.5

 ≥ 500

17

15

88.2

2

11.8

CA19-9 (U/ml)

0.059

 < 27

35

32

91.4

3

8.6

 ≥ 27

22

16

72.7

6

27.3

HE4 (pmol/L)

0.251

 < 140

29

26

89.7

3

10.3

 ≥ 140

28

22

78.6

6

21.4

Ascites

0.702

 None

16

13

81.3

3

18.7

 Yes

41

35

85.4

6

14.6

Tumor diameter (cm)

0.040

 < 10

24

23

95.8

1

4.2

 ≥ 10

33

25

75.8

8

24.2

Whether bilateral

0.051

 Yes

15

15

100.0

0

0

 No

42

33

78.6

9

21.4

Pathological lymph node metastasis (pN)

0.157

 None

48

39

81.3

9

18.7

 Yes

9

9

100.0

0

0

Whether recur

0.026

 Yes

18

18

100.0

0

0

 No

39

30

76.9

9

23.1